% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. Message Board

  • lilgodfther lilgodfther Jul 2, 2013 9:58 AM Flag

    Seking Alpha E-Mail, Price Target $22.00

    9:50 AM "We remain positive on the Phase 3 data for ganetespib in 2014," notes Jefferies analyst Thomas Wei of Synta Pharmaceuticals' (SNTA +0.8%) lead drug candidate. Wei says "incremental geographic data from [a] recent analysis the GALAXY-1 trial … support the efficacy profile" of the drug. The stock is still stinging from losses incurred last month after an increase in the Hazard ratio in clinical trials made investors nervous. Nonetheless, Jefferies maintains a Buy rating and a $22 PT. Read comments

    SNTA price at time of publication: $5.04. Check SNTA price now »

0.3430.000(0.00%)Jul 22 3:59 PMEDT